Trial NCT03287050

View at ClinicalTrials.gov 
Org. Study IDs: UMCC 2017.069
Secondary IDs: HUM00135161

Last trial update was posted on 2021-12-15

MeSH Interventions

Pembrolizumab

MeSH Conditions

Carcinoma Carcinoma, Transitional Cell

Other Conditions

Urothelial Carcinoma

Stopping Reasons

due to changing therapeutic landscape in metastatic bladder cancer and lack of radiation/immunotherapy systemic synergy in other malignancies

Limitations And Caveats

This study was closed early (at 6 patients) due to changing therapeutic landscape in metastatic bladder cancer and lack of radiation/immunotherapy systemic synergy in other malignancies.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID